Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in the United States, including both community and academic treatment settings.

Inclusion Criteria: * Age 19 or over at time of informed consent. * Diagnosis of metastatic renal cell cancer (mRCC) with less than or equal to (≤) 3 months of first-line systemic therapy or less than or equal to (≤) 3 months of second-line systemic therapy for mRCC. 1. Prior surgery and radiation therapy are permitted. 2. Prior neoadjuvant and adjuvant therapy for non-metastatic renal cell carcinoma are permitted. 3. Patients currently not on therapy and being observed are permitted. * Evidence of signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study. * Ability to comply with completion of PROs Exclusion Criteria: * Patients being treated for metastatic solid tumors other than mRCC are excluded. Non-cytotoxic oral agents for adjuvant or maintenance therapy of other cancers are permitted. * Patients who are not intending to undergo follow up care at a study site within PCORnet